Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1986 1
1987 1
1989 1
1991 1
1993 1
1994 4
1995 2
1996 2
1997 3
1998 1
1999 5
2000 5
2001 2
2002 2
2003 2
2004 3
2005 5
2006 1
2007 3
2008 6
2009 6
2010 4
2011 2
2012 5
2013 1
2014 1
2015 1
2019 2
2020 2
2022 1
2023 1
2024 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials.
Menshawy A, Ismail A, Abdel-Maboud M, El-Din AA, Elgebaly A, Gadelkarim M, Bahbah EI, Abdelghany MF, Samy A, Abbas AM. Menshawy A, et al. J Gynecol Obstet Hum Reprod. 2019 Nov;48(9):763-770. doi: 10.1016/j.jogoh.2019.03.025. Epub 2019 Mar 30. J Gynecol Obstet Hum Reprod. 2019. PMID: 30940512
Hormonal treatment with oral contraceptives, containing estrogen (ethinyl-estradiol, EE) with progestogen (drospirenone, DRSP) or (chlormadinone acetate, CMA), has improved symptoms and biomarkers of PCOS. OBJECTIVE: The aim of the present meta-analysis is to compar …
Hormonal treatment with oral contraceptives, containing estrogen (ethinyl-estradiol, EE) with progestogen (drospirenone, DRSP) or (chlorm …
Risk of venous thromboembolism associated with chlormadinone acetate- and levonorgestrel-containing combined oral contraceptives - Insights from the retrospective RIVET-RCS study.
De Corte P, Klinghardt M, Bauerfeind A, Boehnke T, Heinemann K. De Corte P, et al. Contraception. 2026 Jan;153:111251. doi: 10.1016/j.contraception.2025.111251. Epub 2025 Oct 9. Contraception. 2026. PMID: 41067517
OBJECTIVE: We assessed the risk of venous thromboembolism (VTE) risk of chlormadinone acetate (CMA) 2 mg/ethinylestradiol (EE) 30 g as opposed to levonorgestrel (LNG) 0.15 mg/EE 30 g. ...
OBJECTIVE: We assessed the risk of venous thromboembolism (VTE) risk of chlormadinone acetate (CMA) 2 mg/ethinylestradiol (EE) …
A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.
Sugimoto M, Kakehi Y, Horie S, Hirao Y, Akaza H. Sugimoto M, et al. Jpn J Clin Oncol. 2022 Feb 5;52(2):187-196. doi: 10.1093/jjco/hyab162. Jpn J Clin Oncol. 2022. PMID: 34698353 Free PMC article. Clinical Trial.
OBJECTIVES: This study was conducted to evaluate the effect of low-dose chlormadinone acetate, an antiandrogen agent, on the persistence rate of active surveillance in patients with low-risk prostate cancer. ...The number of positive cores at 12 and 36 months biopsy …
OBJECTIVES: This study was conducted to evaluate the effect of low-dose chlormadinone acetate, an antiandrogen agent, on the p …
Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause.
Pélissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Jondet M. Pélissier C, et al. Maturitas. 2001 Oct 31;40(1):85-94. doi: 10.1016/s0378-5122(01)00170-0. Maturitas. 2001. PMID: 11684377 Clinical Trial.
OBJECTIVE: The efficacy and safety of chlormadinone acetate (CA) versus micronized progesterone (P) were assessed in non-hysterectomized postmenopausal women. ...
OBJECTIVE: The efficacy and safety of chlormadinone acetate (CA) versus micronized progesterone (P) were assessed in non-hyste …
Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis.
Matsukawa A, Yanagisawa T, Bekku K, Parizi MK, Laukhtina E, Klemm J, Chiujdea S, Mori K, Kimura S, Miki J, Pradere B, Rivas JG, Gandaglia G, Kimura T, Kasivisvanathan V, Ploussard G, Cornford P, Shariat SF, Rajwa P. Matsukawa A, et al. Eur Urol Oncol. 2024 Jun;7(3):376-400. doi: 10.1016/j.euo.2023.10.010. Epub 2023 Oct 28. Eur Urol Oncol. 2024. PMID: 38277189 Free article.
The interventions considered in the studies included 5-alpha reductase inhibitors (5-ARIs), statins, diet, exercise, chlormadinone, fexapotide triflutate (FT), enzalutamide, coffee, vitamin D3, and PROSTVAC. We found that administration of 5-ARIs was associated with improv …
The interventions considered in the studies included 5-alpha reductase inhibitors (5-ARIs), statins, diet, exercise, chlormadinone, f …
Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group.
Okada H, Kawaida N, Ogawa T, Arakawa S, Matsumoto O, Kamidono S. Okada H, et al. Scand J Urol Nephrol. 1996 Oct;30(5):379-85. doi: 10.3109/00365599609181314. Scand J Urol Nephrol. 1996. PMID: 8936627 Clinical Trial.
To investigate whether the combination of tamsulosin with the anti-androgenic drug chlormadinone is of further therapeutic benefit, 80 patients randomly received tamsulosin 0.2 mg daily, chlormadinone 50 mg daily or a combination of tamsulosin 0.2 mg and chlormad …
To investigate whether the combination of tamsulosin with the anti-androgenic drug chlormadinone is of further therapeutic benefit, 8 …
Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
Bonn M, Eydeler U, Barkworth M, Rovati LC. Bonn M, et al. Arzneimittelforschung. 2009;59(12):651-8. doi: 10.1055/s-0031-1296455. Arzneimittelforschung. 2009. PMID: 20108652 Clinical Trial.
For chlormadinone acetate, geometric means of AUC(0-infinity) were 53.322 ng/ml x h (test) and 58.111 ng/ml x h (reference). ...Regarding the AUC(0-infinity) ratio of chlormadinone acetate, the point estimator is 91.60% and the 90% confidence interval …
For chlormadinone acetate, geometric means of AUC(0-infinity) were 53.322 ng/ml x h (test) and 58.111 ng/ml x h (reference). . …
Comparison of change in body weight between contraception containing 30-mug ethinylestradiol/2-mg chlormadinone acetate or 30-mug ethinylestradiol/3-mg drospirenone: a randomised controlled trial.
Wongwananuruk T, Panichyawat N, Panchalee T, Jirakittidul P, Angsuwathana S, Sirimai K, Thamkhantho M, Chiravacharadej G. Wongwananuruk T, et al. Eur J Contracept Reprod Health Care. 2020 Feb;25(1):43-48. doi: 10.1080/13625187.2019.1688290. Epub 2019 Nov 22. Eur J Contracept Reprod Health Care. 2020. PMID: 31756117 Clinical Trial.
Objectives: The aim of this study was to compare changes in body weight in women using a combined oral contraceptive (COC) consisting of 30-mug ethinylestradiol (EE) and 2-mg chlormadinone acetate (CMA) or a COC consisting of 30-mug EE and 3-mg drospirenone (DRSP).M …
Objectives: The aim of this study was to compare changes in body weight in women using a combined oral contraceptive (COC) consisting of 30- …
Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium.
Franceschini SA, Vieira CS, Martins WP, França JB, Ferriani RA. Franceschini SA, et al. Contraception. 2013 Jun;87(6):766-72. doi: 10.1016/j.contraception.2012.09.023. Epub 2012 Oct 25. Contraception. 2013. PMID: 23102798 Clinical Trial.
The present study evaluated the effects on the endothelium of healthy women of combinations of 30 mcg ethinylestradiol (EE)/2 mg chlormadinone acetate (CMA) and 30 mcg EE/150 mcg levonorgestrel (LNG). STUDY DESIGN: Sixty-four healthy women were evaluated, 21 using a …
The present study evaluated the effects on the endothelium of healthy women of combinations of 30 mcg ethinylestradiol (EE)/2 mg chlormad …
A five-day gradual reduction regimen of chlormadinone reduces premenstrual anxiety and depression: a pilot study.
Contreras CM, Azamar-Arizmendi G, Saavedra M, Hernández-Lozano M. Contreras CM, et al. Arch Med Res. 2006 Oct;37(7):907-13. doi: 10.1016/j.arcmed.2006.05.001. Arch Med Res. 2006. PMID: 16971235 Clinical Trial.
METHODS: The present study is a pilot, controlled, double-blind study exploring the effectiveness of a premenstrual 5-day gradual reduction regimen of chlormadinone acetate on PMDD. Volunteers received an initial dose of 10 mg (five 2-mg tablets) on the 24(th) day o …
METHODS: The present study is a pilot, controlled, double-blind study exploring the effectiveness of a premenstrual 5-day gradual reduction …
72 results